Subcutaneous ketamine reduces suicide risk and improves functioning in depression: A proof-of-concept study

This publication has 25 references indexed in Scilit:

• Designing Clinical Trials to Assess the Impact of Pharmacological Treatment for Suicidal Ideation/Behavior: Issues and Potential Solutions
  Pharmaceutical Medicine, 2023
• Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability
  The Lancet Psychiatry, 2022
• Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression
  Clinical Drug Investigation, 2022
• Implementation of Columbia Suicide Severity Rating Scale (C-SSRS) as a Universal Suicide Risk Screening tool in a High Volume Emergency Department
  Archives of Suicide Research, 2022
• CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity
  Neuropharmacology, 2022
• Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial
  Depression and Anxiety, 2019
• Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial
  Journal of Affective Disorders, 2019
• Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression
  The American Journal of Geriatric Psychiatry, 2017
• Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
  Nature Medicine, 2016
• Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
  Current Opinion in Neurobiology, 2015